GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » Profitability Rank

OBI Pharma (ROCO:4174) Profitability Rank : 2 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is OBI Pharma Profitability Rank?

OBI Pharma has the Profitability Rank of 2. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

OBI Pharma's Operating Margin % for the quarter that ended in Mar. 2024 was -6,245.80%. As of today, OBI Pharma's Piotroski F-Score is 3.


Competitive Comparison of OBI Pharma's Profitability Rank

For the Biotechnology subindustry, OBI Pharma's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OBI Pharma's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OBI Pharma's Profitability Rank distribution charts can be found below:

* The bar in red indicates where OBI Pharma's Profitability Rank falls into.



OBI Pharma Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

OBI Pharma has the Profitability Rank of 2. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

OBI Pharma's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-570.554 / 9.135
=-6,245.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

OBI Pharma has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Good Sign:

OBI Pharma Inc operating margin is expanding. Margin expansion is usually a good sign.

4. Consistency of the profitability

5. Predictability Rank


OBI Pharma Profitability Rank Related Terms

Thank you for viewing the detailed overview of OBI Pharma's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


OBI Pharma (ROCO:4174) Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Park Street, Room. 1907, 19th Floor, Nangang District, Taipei, TWN, 115
OBI Pharma Inc is part of the healthcare sector. The company and its subsidiaries are engaged in new drug research. Its focus is on the unmet medical need in challenging diseases throughout the world, such as cancer. OBI strives to improve health and the quality of life through cost-effective therapeutics. The Group has four reportable segments, which are the anti-cancer new drug segment, bispecific monoclonal antibody new drug segment, botulinum toxin new drug segment, and CDMO segment.

OBI Pharma (ROCO:4174) Headlines

No Headlines